ImmunityBio Inc IBRX 深 沪
已收盘 05-08 16:00:00 美东时间
8.51
+0.750
+9.66%
华盛通- 最 高8.56
- 今 开7.88
- 成交量 1619.94万股
- 最 低 7.58
- 昨 收 7.76
- 总市值 89.13亿
- 52周最高 12.43
- 市盈率 静 --
- 换手率 1.55%
- 52周最低 1.95
- 委 比 -91.79%
- 总股本 10.47亿
- 历史最高 45.42
- 量 比 1.20
- 振 幅 12.63%
- 历史最低 0.93
- 每 手 1
- 风险率 2.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmunityBio Q1 EPS $(0.62) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.07) by 785.71 percent. This is a 313.33 percent decrease over losses of $(0.15) per share from
05-07 21:09
财报速睇 | ImmunityBio Inc 2026财年Q1营收0.44亿美元，同比增长158.8%；归母净利润亏损6.33亿美元，同比亏损扩大386.9%
华盛资讯5月7日讯，ImmunityBio Inc公布2026财年Q1业绩，公司Q1营收0.44亿美元，同比增长158.8%，归母净利润亏损6.33亿美元，同比亏损扩大386.9%。
05-07 19:51
财报速睇 | ImmunityBio Inc 2026财年Q1营收0.44亿美元，同比增长167.6%；归母净利润亏损6.33亿美元，同比亏损扩大388.1%
华盛资讯5月7日讯，ImmunityBio Inc公布2026财年Q1业绩，公司Q1营收0.44亿美元，同比增长167.6%，归母净利润亏损6.33亿美元，同比亏损扩大388.1%。
05-07 19:47
Why ImmunityBio Stock Is Surging On Wednesday?
ImmunityBio (IBRX) stock is surging. Read why Patrick Soon-Shiong's manufacturing updates and new ANKTIVA comparative data have retail traders bullish.
05-07 01:26
ImmunityBio To Present New Treatment Comparison Results Evaluating ANKTIVA Plus BCG Versus Nadofaragene Firadenovec-Vncg And TAR-200 In Patients With NMIBC CIS, With Or Without Papillary Disease, At AUA 2026
Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, durability, and safety
05-05 19:36
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa., April 24, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action l...
04-25 04:40
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In
The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and Lucid.
04-21 23:56
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia
ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after it launched ANKTIVA in Saudi Arabia for bladder and lung cancer.
04-21 21:44
ImmunityBio Faces Lawsuit Over Anktiva Promotion After FDA Warning Letter
ImmunityBio(IBRX) is facing a securities lawsuit alleging that the compan...
04-17 03:42
Why Is ImmunityBio Stock Rallying Thursday?
ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning prompts review of promotional claims.
04-10 02:11
